AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30646926 — intervention group
Group type: EXPERIMENTAL
Intervention: LOWFODMAP diet (16.06 ± 1.79 g·d‐ 1)
Number of subjects: 16
Study 30646926 — intervention group
Group type: EXPERIMENTAL
Intervention: LOWFODMAP diet
Number of subjects: 16
Study 30646926 — intervention group
Group type: COMPARATOR
Intervention: HIGHFODMAP diet (38.65 ± 6.66 g·d‐ 1)
Number of subjects: 16
Study 29577324 — intervention group
Group type: EXPERIMENTAL
Intervention: Stored autologous RBC transfusion
Number of subjects: 18
Study 29577324 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh RBC transfusion
Number of subjects: 18
Study 29577324 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 18
Study 29577324 — intervention group
Group type: EXPERIMENTAL
Intervention: Stored RBC transfusion
Number of subjects: 18
Study 27230850 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg once daily (QD) on days 1 and 5 in patients with mild renal impairment (N=8)
Number of subjects: 30
Study 27230850 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg once daily (QD) on days 1 and 5 in patients with moderate renal impairment (N=8)
Number of subjects: 30
Study 27230850 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg once daily (QD) on days 1 and 5 in patients with severe renal impairment (N=6)
Number of subjects: 30
Study 27230850 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (CrCl >80 mL/min)
Number of subjects: 30
Study 25098025 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hLH 2,750 IU
Number of subjects: 67
Study 25098025 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hLH 5,500 IU
Number of subjects: 67
Study 25098025 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hLH 11,000 IU
Number of subjects: 67
Study 25098025 — intervention group
Group type: EXPERIMENTAL
Intervention: u-hCG 5,000 IU
Number of subjects: 67
Study 25098025 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hLH 825 IU
Number of subjects: 67
Study 25098025 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hLH 22,000 IU
Number of subjects: 67
Study 25098025 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 67
Study 21935705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar 20 mg
Number of subjects: 98
Study 21935705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar 40 mg
Number of subjects: 98
Study 21935705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar 5 mg/day
Number of subjects: 98
Study 21935705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar 1 mg/day
Number of subjects: 98
Study 21935705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar 3 mg/day
Number of subjects: 98
Study 21935705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 21122285 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy with ESWT (shock waves) and proprioceptive Multi Joint System, along with a specific nutritional supplement.
Number of subjects: 80
Study 21122285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement in Group B2.
Number of subjects: 80
Study 21122285 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B1 without nutritional supplement).
Number of subjects: 80
Study 17438307 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (three 60-minute sessions per week for 4 months)
Number of subjects: 20
Study 17438307 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 20
Study 17438307 — intervention group
Group type: COMPARATOR
Intervention: Untrained hypertensive patients
Number of subjects: 20
Study 15854093 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced sternal-closure system
Number of subjects: 40
Study 15854093 — intervention group
Group type: COMPARATOR
Intervention: Standard stainless steel wires (Control)
Number of subjects: 40
Study 12378386 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 207
Study 12378386 — intervention group
Group type: COMPARATOR
Intervention: No diabetes (Control)
Number of subjects: 207
Study 11232674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg once a day in the evening
Number of subjects: 120
Study 11232674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg once a day in the morning
Number of subjects: 120
Study 11232674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 120
Study 11232674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.i.d.
Number of subjects: 120
Study 9923581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg orally once daily for 5 days
Number of subjects: 10
Study 9923581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8151602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal BP monitoring every 15 minutes (session A)
Number of subjects: 24
Study 8151602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal BP monitoring every 60 minutes (session B)
Number of subjects: 24
Study 3045100 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 70
Study 3045100 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 70
Study 3045100 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 70
Study 3045100 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise multiple regression analysis
Number of subjects: 70
Study 31806133 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 16740
Study 29173320 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born extremely prematurely
Number of subjects: 303
Study 29173320 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born prematurely with BPD
Number of subjects: 303
Study 29173320 — intervention group
Group type: COMPARATOR
Intervention: Children born at term
Number of subjects: 303
Study 25466664 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing foods enriched with ω‐3 fatty acids, β‐glucans, phytosterols, and vitamin E
Number of subjects: 16
Study 25466664 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic diet without the active components
Number of subjects: 16
Study 23522354 — intervention group
Group type: EXPERIMENTAL
Intervention: Neusidl Corneal Inserter (Fischer Surgical Inc)
Number of subjects: 79
Study 23522354 — intervention group
Group type: COMPARATOR
Intervention: Charlie II insertion forceps (Bausch & Lomb Surgical)
Number of subjects: 79
Study 23522354 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study 21410371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine (200 mg/m² continuous IV infusion for 24 hours in cycle 1 and 1000 mg/m² by infusion for 3 hours twice daily in cycle 2)
Number of subjects: 860
Study 21410371 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine (1000 mg/m² every 12 hours in cycle 1 and 2000 mg/m² twice daily in cycle 2)
Number of subjects: 860
Study 19713849 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation
Number of subjects: 0
Study 19713849 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 17166332 — intervention group
Group type: EXPERIMENTAL
Intervention: α1-adrenergic receptor antagonists (α1-AR)
Number of subjects: 0
Study 17166332 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase type 5 inhibitors (PDE-5s)
Number of subjects: 0
Study 17166332 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of α1-AR antagonist and PDE-5
Number of subjects: 0
Study 15909750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol therapy
Number of subjects: 60
Study 15909750 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ethambutol)
Number of subjects: 60
Study 11883023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ante partum perineal massage
Number of subjects: 4
Study 9196083 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb-E25 (2 mg/kg on Day 0 and 1 mg/kg on Days 7, 14, 28, 42, 56, and 70)
Number of subjects: 11
Study 9196083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8308939 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional alcoholism treatment for alcohol and cocaine abusers
Number of subjects: 100
Study 8308939 — intervention group
Group type: COMPARATOR
Intervention: Traditional alcoholism treatment for alcohol-only patients
Number of subjects: 100
Study 3083718 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg nicardipine
Number of subjects: 47
Study 3083718 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg nicardipine
Number of subjects: 47
Study 3083718 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg nicardipine
Number of subjects: 47
Study 31796488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral FCR intervention consisting of an intake with the GP and five sessions with the MHW.
Number of subjects: 0
Study 31796488 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 0
Study 30021518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric Balloon (IB)
Number of subjects: 150
Study 30021518 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal-Jejunal Bypass Liner (DJBL)
Number of subjects: 150
Study 30021518 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 150
Study 30021518 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (IB, DJBL, Sham)
Number of subjects: 150
Study 26563940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-structured doxycycline films
Number of subjects: 150
Study 26563940 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline films
Number of subjects: 150
Study 26563940 — intervention group
Group type: COMPARATOR
Intervention: Placebo films
Number of subjects: 150
Study 25486273 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) - 1 minute at ∼ 100% W peak and 1 minute at ∼ 20% W peak for 20 minutes
Number of subjects: 44
Study 25486273 — intervention group
Group type: COMPARATOR
Intervention: Continuous Moderate-Intensity Exercise (CMI) - ∼ 40% W peak for 40 minutes
Number of subjects: 44
Study 25486273 — intervention group
Group type: COMPARATOR
Intervention: Continuous Vigorous-Intensity Exercise (CVI) - ∼ 80% W peak for 20 minutes
Number of subjects: 44
Study 25486273 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT
Number of subjects: 44
Study 21604211 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction diet combined with aerobic exercises
Number of subjects: 40
Study 21604211 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction diet
Number of subjects: 40
Study 21059586 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Number of subjects: 57
Study 21059586 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control condition
Number of subjects: 57
Study 17701271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (10,000 lux, n = 10)
Number of subjects: 15
Study 17701271 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (600 lux, n = 5)
Number of subjects: 15
Study 15860501 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (ganirelix) administered daily from the 8th day of stimulation
Number of subjects: 148
Study 15860501 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (triptorelin) long protocol
Number of subjects: 148
Study 12595851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (mean dose 4.1 +/- 1.4 microg/kg/min)
Number of subjects: 36
Study 12595851 — intervention group
Group type: COMPARATOR
Intervention: Milrinone (mean dose 0.39 +/- 1.0 microg/kg/min)
Number of subjects: 36
Study 12595851 — intervention group
Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 36
Study 10528419 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg per day for 24 weeks
Number of subjects: 76
Study 7860736 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol in cerebrospinal fluid (CSF)
Number of subjects: 10
Study 7860736 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol in plasma
Number of subjects: 10
Study 7860736 — intervention group
Group type: COMPARATOR
Intervention: CSF concentrations of mannitol, sorbitol, galactitol, ribitol, arabitol, or 1,5-anhydrosorbitol
Number of subjects: 10
Study 7860736 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma mannitol, ribitol, and arabitol
Number of subjects: 10
Study 1683336 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 41
Study 1683336 — intervention group
Group type: COMPARATOR
Intervention: Perazine
Number of subjects: 41
Study 7084138 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral information about medications at initial interview
Number of subjects: 50
Study 7084138 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information to take home
Number of subjects: 50
Study 7084138 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact only
Number of subjects: 50
Study 7084138 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral and written information
Number of subjects: 50
Study 7084138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study 3971235 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphlebitic mixture of heparin‐hydrocortisone‐sodium bicarbonate
Number of subjects: 30
Study 3971235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31862762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic prednisone
Number of subjects: 153
Study 31862762 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylactic prednisone)
Number of subjects: 153
Study 28987341 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate group intervention
Number of subjects: 1700
Study 28987341 — intervention group
Group type: COMPARATOR
Intervention: Delayed group intervention
Number of subjects: 1700
Study 28987341 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention effectiveness
Number of subjects: 1700
Study 26350486 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression/anxiety symptoms
Number of subjects: 379
Study 26350486 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent depression/anxiety symptoms
Number of subjects: 379
Study 26350486 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with symptoms of depression/anxiety at baseline
Number of subjects: 379
Study 24762026 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention including motivational aspects, cognitive aspects, and training in inhalation techniques
Number of subjects: 146
Study 24762026 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 146
Study 22609118 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported height
Number of subjects: 125
Study 22609118 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported weight
Number of subjects: 125
Study 22609118 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported BMI
Number of subjects: 125
Study 20406512 — intervention group
Group type: EXPERIMENTAL
Intervention: SpiroPro pneumotachometer tube after 5-9 disinfections
Number of subjects: 10
Study 20406512 — intervention group
Group type: EXPERIMENTAL
Intervention: SpiroPro pneumotachometer tube after 10 disinfections
Number of subjects: 10
Study 20406512 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous rinsing in distilled water and repeated calibration checks
Number of subjects: 10
Study 20406512 — intervention group
Group type: EXPERIMENTAL
Intervention: Single use of SpiroPro pneumotachometers
Number of subjects: 10
Study 18458872 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 9
Study 18458872 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 9
Study 16150608 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural correction during seated typing postures (corrected posture)
Number of subjects: 18
Study 16150608 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural correction during standing postures (corrected posture)
Number of subjects: 18
Study 16150608 — intervention group
Group type: COMPARATOR
Intervention: Habitual posture during seated typing
Number of subjects: 18
Study 16150608 — intervention group
Group type: COMPARATOR
Intervention: Forward head posture during seated typing
Number of subjects: 18
Study 16150608 — intervention group
Group type: EXPERIMENTAL
Intervention: Masseter muscle activation
Number of subjects: 18
Study 11171713 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 22
Study 11171713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9764154 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 309
Study 9764154 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun
Number of subjects: 309
Study 10155556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) with corticosteroids (CS) and plasma exchanges (PE)
Number of subjects: 236
Study 10155556 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and PE
Number of subjects: 236
Study 10155556 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term steroid therapy and PE with anti-viral therapy
Number of subjects: 236
Study 10155556 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchanges (PE)
Number of subjects: 236
Study 10155556 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone in association with CYC
Number of subjects: 236
Study 10155556 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-viral agents and PE
Number of subjects: 236
Study 3402096 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 832
Study 3402096 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 832
Study 29928869 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal cryoablation (CRYO)
Number of subjects: 46
Study 29928869 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 46
Study 26252875 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily and asunaprevir 100 mg twice daily for 24 weeks
Number of subjects: 230
Study 26252875 — intervention group
Group type: COMPARATOR
Intervention: Telaprevir 750 mg three times daily for 12 weeks and peginterferon/ribavirin for 24 weeks
Number of subjects: 230
Study 26252875 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir + asunaprevir
Number of subjects: 230
Study 26252875 — intervention group
Group type: COMPARATOR
Intervention: Telaprevir + peginterferon/ribavirin
Number of subjects: 230
Study 25313512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 36
Study 25313512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22551104 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic testing (n=315)
Number of subjects: 630
Study 22551104 — intervention group
Group type: COMPARATOR
Intervention: Evaluation only (n=315)
Number of subjects: 630
Study 20817281 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily)
Number of subjects: 17263
Study 20817281 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel
Number of subjects: 17263
Study 20817281 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (300 mg on day 1 then 75 mg daily)
Number of subjects: 17263
Study 20817281 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin (300-325 mg daily)
Number of subjects: 17263
Study 20817281 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (75-100 mg daily)
Number of subjects: 17263
Study 20817281 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin
Number of subjects: 17263
Study 20817281 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin
Number of subjects: 17263
Study 18623043 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg oral dose
Number of subjects: 24
Study 15858525 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-centered adaptations (tailoring multi-component interventions, using interpersonal contacts for participant maintenance, non-blinding of trial participants)
Number of subjects: 0
Study 12391441 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (20 min at 80% of estimated maximum cardiorespiratory endurance)
Number of subjects: 50
Study 12391441 — intervention group
Group type: COMPARATOR
Intervention: Control group (watched a 20 min emotionally neutral video)
Number of subjects: 50
Study 9448150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 53
Study 9448150 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (Control)
Number of subjects: 53
Study 7611285 — intervention group
Group type: EXPERIMENTAL
Intervention: Written materials
Number of subjects: 346
Study 7611285 — intervention group
Group type: EXPERIMENTAL
Intervention: Video materials
Number of subjects: 346
Study 2616352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate pretreatment (1-g dose at 6 and 2 hours before ciprofloxacin)
Number of subjects: 12
Study 2616352 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin alone
Number of subjects: 12
Study 328034 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 810
Study 31237158 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 6006
Study 31237158 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 6006
Study 31237158 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 6006
Study 29752024 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 268896
Study 29752024 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine plus behavioral change
Number of subjects: 268896
Study 29752024 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention
Number of subjects: 268896